Gilead Sciences and Nurix Extend Research Collaboration for Two Years
Tuesday, 2 April 2024, 12:20
Gilead Sciences and Nurix Extend Research Collaboration
In a strategic move, Gilead Sciences (GILD) and Nurix Therapeutics (NRIX) have chosen to extend their research collaboration for an additional two years. This extension also includes additional payments, showcasing a deepened commitment to their partnership. The decision is likely to have an impactful influence on the pharmaceutical industry.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.